Royalty Pharma PLC $RPRX Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC decreased its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 75.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,998 shares of the biopharmaceutical company’s stock after selling 181,710 shares during the quarter. Hsbc Holdings PLC’s holdings in Royalty Pharma were worth $2,253,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LM Advisors LLC acquired a new stake in Royalty Pharma during the fourth quarter worth approximately $26,000. Lloyd Advisory Services LLC. acquired a new position in shares of Royalty Pharma in the 4th quarter valued at $30,000. Private Trust Co. NA boosted its holdings in shares of Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares in the last quarter. CIBC Private Wealth Group LLC grew its position in shares of Royalty Pharma by 66.4% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 446 shares during the last quarter. Finally, Larson Financial Group LLC grew its position in shares of Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $56.43 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The business’s fifty day moving average price is $54.35 and its two-hundred day moving average price is $47.90. The stock has a market cap of $32.49 billion, a PE ratio of 38.39, a price-to-earnings-growth ratio of 1.59 and a beta of 0.43. Royalty Pharma PLC has a one year low of $34.08 and a one year high of $58.84.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The company had revenue of $630.58 million during the quarter, compared to analysts’ expectations of $881.69 million. On average, analysts forecast that Royalty Pharma PLC will post 5.06 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date was Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Wall Street Analysts Forecast Growth

RPRX has been the subject of a number of research reports. Weiss Ratings cut shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 15th. Citigroup raised their price objective on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. raised their price objective on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, UBS Group boosted their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $53.71.

Insider Activity

In other Royalty Pharma news, EVP Christopher Hite sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the sale, the executive vice president directly owned 559,399 shares of the company’s stock, valued at $30,431,305.60. This trade represents a 21.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of Royalty Pharma stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.06, for a total transaction of $726,073.04. Following the sale, the executive vice president owned 31,881 shares of the company’s stock, valued at approximately $1,691,605.86. This trade represents a 30.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 427,800 shares of company stock worth $23,333,723. Company insiders own 18.84% of the company’s stock.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.